A
A. J. M. Eerenberg-Belmer
Researcher at University of Amsterdam
Publications - 13
Citations - 1590
A. J. M. Eerenberg-Belmer is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Sepsis & Septic shock. The author has an hindex of 10, co-authored 13 publications receiving 1555 citations.
Papers
More filters
Journal ArticleDOI
Increased plasma levels of interleukin-6 in sepsis.
C. E. Hack,E. de Groot,R. J. F. Felt-Bersma,J. H. Nuijens,R.J.M. Strack van Schijndel,A. J. M. Eerenberg-Belmer,L. G. Thijs,Lucien A. Aarden +7 more
TL;DR: Levels of IL-6 on admission appeared to be of prognostic significance: levels were higher in septic patients who subsequently died than in those who survived, in particular when only patients with septic shock were considered.
Journal ArticleDOI
Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis
C. Erik Hack,Jan H. Nuijens,Richel J.F. Felt-Bersma,Willem O. Schreuder,A. J. M. Eerenberg-Belmer,J. Paardekooper,Willem Bronsveld,Lambert G. Thijs +7 more
TL;DR: It is proposed that activation of the complement system via the classical pathway is involved in the development of fatal complications in sepsis.
Journal ArticleDOI
Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.
J. H. Nuijens,C. C. M. Huijbregts,A. J. M. Eerenberg-Belmer,J. J. Abbink,R.J.M. Strack van Schijndel,R. J. F. Felt-Bersma,L. G. Thijs,C. E. Hack +7 more
TL;DR: Low plasma Cl(-)-Inh complex levels during sepsis may not properly reflect the extent of contact activation, and highly sensitive radioimmunoassays for factor XIIa-Cl(- )-inhibitor and kallikrein-Cl-Inh complexes are developed.
Journal ArticleDOI
Proteolytic inactivation of plasma C1- inhibitor in sepsis.
J. H. Nuijens,A. J. M. Eerenberg-Belmer,C. C. M. Huijbregts,W. O. Schreuder,R. J. F. Felt-Bersma,J. J. Abbink,L. G. Thijs,C. E. Hack +7 more
TL;DR: It is proposed that the cleavage of C1-Inh in patients with sepsis reflects processes that play a major role in the development of fatal complications during sepsi.
Journal Article
Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.
L. G. Thijs,C. E. Hack,R.J.M. Strack van Schijndel,J. H. Nuijens,Gertjan Wolbink,A. J. M. Eerenberg-Belmer,H.L.J.A. van der Vall,John Wagstaff +7 more
TL;DR: Administration of IL-2 induces a dose-dependent activation of the complement system in vivo, which appeared to be related to the development of side effects of this therapy, such as the VLS.